Artin Soroosh, Graduate Student, Joins Padua Lab - July 2018
Artin's general research interests lie in the pathogenesis of diseases, with a particular passion for inflammatory bowel disease (IBD). His PhD work at UCLA will consist of uncovering novel epigenetic targets for therapeutic intervention with the ultimate goal of developing drugs to treat IBD. Meet our team >
Padua Lab Members Participate in UCLA Undergraduate Research Day - May 2018
Padua Lab members, Ali Lokhandwala, Lorraine Rowe, and Raymond Huang, participated in the UCLA Undergraduate Research Poster Day. This event highlights undergraduate research in all majors. It provides an exciting opportunity for our undergrads to showcase their research and present it to the UCLA community, alumni, and visitors. The UCLA Undergraduate Research Poster Day has been ongoing for the past four years and this year involved more than 900 undergraduate researchers.
David Padua, MD, PhD, Quoted – Biosimilar Agent Encouraging in IBD Trial - Gastroenterology and Endoscopy News - April 2018
A biosimilar of infliximab appeared to perform as well as the originator drug for the treatment of inflammatory bowel disease, according to interim results from an ongoing multicenter, randomized, controlled, double-blind trial in the Netherlands. “We have a lot of patients on anti–tumor necrosis factor therapies that are doing well,” said David Padua, MD, PhD, the associate director of GI fellowship program. “If, for insurance reasons or other reasons, they switch over to a biosimilar, as a clinician I’d be concerned whether that drug is going to work as effectively. And this study helps to allay some of those fears, and gives clinicians more confidence that they’re able to actually give the biosimilar without significant adverse effects to their patient care.” Read full article >
David Padua, MD, PhD Receives Kenneth Rainin Foundation Award - January 2018
The Kenneth Rainin Foundation announced today that it has awarded $1.7 million in grants through its Synergy Awards program. Funding will support teams of researchers who are pursuing collaborative projects aimed at improving the prediction and prevention of Inflammatory Bowel Disease (IBD). “The Rainin Foundation focuses its grants on impacting patient lives, while still maintaining an eye toward discovery science,” said Laura Wilson, PhD, director of Health Strategy and Ventures for the Rainin Foundation. “We want to fund promising ideas from both IBD research and unrelated fields that have the potential to lead to new patient treatments.” The Synergy Awards encourage investigators with differing areas of expertise to pool their talents and resources toward a research goal that would not be possible if they worked independently.
Dr. Padua and Karka Kirkegaard, PhD, Stanford University, were awarded $200,000 for IFNG-AS1 (NEST) long noncoding RNA as a regular of inflammation in IBD patients.
“As an early stage investigator, this type of funding opportunity is critical to me developing a successful scientific career,” said David Padua, MD, PhD, University of California, Los Angeles. “I am looking forward to collaborating with top notch researchers to combine our basic science and clinical translational research toward new discoveries in IBD.”
This story also ran in Science and Technology Research News
David Padua, MD, PhD Receives Crohn's and Colitis Foundation Career Development Award - June 2017
The Crohn’s & Colitis Foundation is a leading funder of basic and clinical research in inflammatory bowel diseases (IBD). The Foundation supports research that increases our understanding of the etiology, pathogenesis, treatment and prevention of these diseases. Career Development Awards are mentored awards intended to facilitate the development of individuals with research potential to prepare for a career of independent basic and/or clinical investigation in the area of IBD.
Drs. Jill Hoffman, Elaine Hsiao, Marina Koutsioumpa and David Padua Receive CURE: Digestive Diseases Research Center (DDRC)/CTSI Pilot Feasibility Award 2017-2018
The CURE:DDRC/CTSI Pilot and Feasibility Awards are for high-quality, innovative research in the biology, function and diseases of the digestive system, with special emphasis on receptor and signal transduction mechanisms, brain-gut interactions, gastrointestinal and pancreatic physiology and inflammation, and mechanisms underlying diseases of the digestive system. The 2017-2018 awards were presented to the following members of the division (1) Jill Hoffman, PhD, postdoctoral fellow, Center for Inflammatory Bowel Diseases, for “The Role of CRHR2 Signaling in Enteric Glial Cell Function During Colitis,” (2) Elaine Hsiao, PhD, assistant professor, UCLA Microbiome Center, for “Dissecting Molecular and Cellular Mechanisms for Communication Across the Microbiota-Gut-Brain Axis,” (3) Marina Koutsioumpa, PhD, postdoctoral fellow, Center for Systems Biomedicine, for “Characterization and Therapeutic Targeting of ING3 Chromatin Pathway in Pancreatic Cancer,” and (4) David Padua, MD, PhD, assistant professor of medicine, for “The Role of the Long-Noncoding RNA, CKDN2B-AS1, in Inflammatory Bowel Disease.”
Dr. Padua Seeks Answers in the Lab That Can Improve Lives of His IBD Patients - Beyond the Scope - Fall 2016
In the Fall 2016 issue of the division's bi-annual newsletter, Beyond the Scope, we introduce Dr. David Padua. Dr. Padua is a new member of our full-time faculty who is conducting important translation research in IBD. Read article >